We fund and support clinical trials which seek to slow, stop or reverse Parkinson’s. Find out about the trials which are recruiting as part of our International Linked Clinical Trials (iLCT) programme developed in partnership with Van Andel Institute.

Please note: The current pandemic has slowed, and in some cases stopped, the recruitment process to these clinical studies. Each site will have guidelines and advice about their own COVID protocols.

The Anle138b Trial

This clinical trial is testing a small molecule called Anle138b to assess its potential to inhibit alpha-synuclein masses accumulating. In Parkinson’s, alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and…

The AZA-PD Trial (azathioprine)

Dr Williams-Gray’s team at the University of Cambridge’s Centre for Parkinson-Plus are conducting a clinical trial of azathioprine (AZA-PD), a medication already used to treat inflammation by dampening down the immune…

The ADepT-PD trial (nortriptyline)

This trial is recruiting 408 people in 30 centres across the UK. Funded by the NIHR with support from Cure Parkinson’s, the trial lead is Professor Anette Schrag, the…

The Bydureon (exenatide) phase 3 trial

Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon phase 3 trial which has begun recruiting from six sites in the UK. This phase 3 efficacy…

News

Research news

PD Frontline

As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of…

The PROSEEK trial – vodobatinib

Sun Pharma Advanced Research Company (SPARC) is conducting a Phase ll clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor vodobatinib (previously known as KO706)…